



PHOSPHAGENICS

Company Announcement

Phosphagenics Signs License Agreement with Intas Pharmaceuticals

04 April 2012 Melbourne, Australia: Melbourne drug delivery technology company Phosphagenics Limited (ASX: POH, OTCQX: PPGNY) has signed a licensing agreement with Intas Pharmaceuticals Ltd, an India based pharmaceuticals company, for the manufacture and sale of three anti-ageing products specifically formulated by Phosphagenics for the Indian market.

Under the terms of the agreement, Intas will pay an undisclosed royalty and will market the new products, incorporating Phosphagenics' patented TPM® technology, through dermatologists and general physicians in India.

Intas officials said that the company will leverage its substantial existing pharmaceutical marketing and sales infrastructure that covers dermatologists and general physicians, to launch this new product line.

Phosphagenics CEO Dr Esra Ogru said the latest Intas agreement was another milestone in the company's commercial strategy to roll out its personal care products globally.

"Our cosmetic lines are gathering momentum internationally and this latest agreement follows on from our arrangement to sell products in the Asian region through the AS Watson and Company chain," she said.

Dr Ogru said India, with a population of over 1.2 billion people represented a large-scale market opportunity for Phosphagenics. It is expected to launch a full dermatological line of personal care products in India if the first three products are a success.

TPM® is a patented topical and transdermal delivery technology which enables superior delivery of various active ingredients into or through the skin.

Phosphagenics Limited

ACN 056 482 403 ABN 32 056 482 403

11 Duerdin Street, Clayton VIC 3168

PO Box 1415, Clayton South MDC VIC 3169 Australia

Tel: +61 (0)3 9565 1119 Fax: +61 (0)3 9565 1151

Web: www.phosphagenics.com Email: info@phosphagenics.com

Ends

Enquiries:

Dr Esra Ogru
Chief Executive Officer
Phosphagenics Limited
+61 3 9565 1119

David Segal
Investor Relations Manager
Phosphagenics Limited
+61 3 9565 1103

Rudi Michelson
Monsoon Communications
+61 3 9620 3333

About Phosphagenics

Phosphagenics is commercialising drug delivery applications based on its novel transdermal (drugs administered via skin) TPM[®] - Targeted Penetration Matrix technology. TPM[®] is a patient friendly and cost effective system used to deliver proven pharmaceutical and nutraceutical products.

The lead product advancing through clinical trials is an oxycodone matrix system for the relief of chronic pain.

Phosphagenics shares are listed on the Australian Securities Exchange (POH) and its ADR . Level 1 program in the US is with The Bank of New York Mellon (PPGNY).
www.phosphagenics.com
www.elixia.com.au

About Intas

Intas is a leading, vertically integrated global pharmaceutical formulation development, manufacturing and marketing company headquartered in India. Intas is ranked as the 12th largest pharmaceutical company in the Indian market with a growth over 27% (as per IMS Health India, Secondary Stockist Audit, January, 2012).

Intas is one of the leading players in chronic therapy areas, also having presence in central nervous system (CNS), cardiovascular system (CVS), diabetology, gastroenterology, dermatology and pain management.

Intas operates 10 manufacturing facilities, 8 of which are in India, and its products are sold in over 50 countries across the globe.
www.intaspharma.com